688189.SHG Hunan Nucien Pharmaceutical Co Ltd
- Market cap
- CNY 1.67B
- P/E
- -
- P/B
- 2.09x
- ROE
- -9.5%
- Dividend yield
- 0.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688189.SHG undervalued?
Graham numberThe Graham number of Hunan Nucien Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Nucien Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Hunan Nucien Pharmaceutical Co Ltd yet.
Hunan Nucien Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Nucien Pharmaceutical Co Ltd
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascular, antibiotics, antipyretics, pain relief, diabetes, analgesic, cerebrovascular,…
Full company profileHunan Nucien Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Nucien Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 278M | 348M | 701M | 1.01B | 1.03B | 744M | 699M | 655M | 252M | 142M | 112M |
| Gross Profit | 168M | 247M | 600M | 899M | 924M | 648M | 600M | 546M | 132M | 44.7M | 16.8M |
| Operating Income | 42.1M | 51.2M | 77.7M | 135M | 161M | -82.6M | 64.6M | 41.6M | -76.7M | -78.2M | -53.9M |
| EBITDA | - | 84.4M | 118M | 163M | 190M | -165M | -2.51M | 31.4M | -333M | -93.2M | -81.8M |
| Net Income | 14.6M | 27.1M | 53.5M | 91.5M | 128M | -162M | -77.5M | -21.3M | -347M | -137M | -74.3M |
| EPS | - | 0.26 | 0.51 | 0.87 | 0.47 | -0.59 | -0.28 | -0.08 | -1.26 | -0.50 | -0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 615M | 603M | 696M | 819M | 2.09B | 2.13B | 1.95B | 1.71B | 1.22B | 809M | 854M |
| Total Liabilities | 443M | 400M | 431M | 461M | 467M | 737M | 658M | 434M | 344M | 97.1M | 144M |
| Shareholders' Equity | 154M | 181M | 234M | 333M | 1.60B | 1.39B | 1.31B | 1.29B | 937M | 784M | 781M |
| Cash & Short-term Investments | 109M | 74.9M | 125M | 155M | 299M | 731M | 713M | 666M | 490M | 302M | 347M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 75.3M | 70.7M | 64.4M | 32.6M | -291M | -63.1M | -160M | 215M | 1.39M | 115M | - |
| Capital Expenditure | 38.5M | 46.5M | 21.5M | 12.8M | 27.5M | 114M | 41.0M | 31.5M | 58.4M | 79.8M | 35.8M |
| Free Cash Flow | - | 24.2M | 42.9M | 19.8M | -318M | -177M | -201M | 184M | -57.0M | 34.8M | -58.9M |
| Ratios | |||||||||||
| ROE | 9.5% | 15.0% | 22.8% | 27.5% | 8.0% | -11.6% | -5.9% | -1.6% | -37.0% | -17.5% | -9.5% |
| ROA | 2.4% | 4.5% | 7.7% | 11.2% | 6.1% | -7.6% | -4.0% | -1.2% | -28.3% | -16.9% | -8.7% |
| Net Profit Margin | 5.3% | 7.8% | 7.6% | 9.0% | 12.4% | -21.8% | -11.1% | -3.2% | -137.7% | -96.5% | -66.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hunan Nucien Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.16%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 17, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.71M | 0.01 | - |
| 2024 | CNY 5.23M | 0.02 | - |
| 2023 | CNY 15.8M | 0.06 | - |
| 2022 | CNY 16.4M | 0.06 | - |
| 2021 | CNY 56.3M | 0.21 | - |
| 2020 | CNY 13.5M | 0.05 | 10.6% |
| 2019 | CNY 15.5M | 0.15 | 16.9% |
| 2018 | CNY 14.2M | 0.14 | 26.6% |
| 2017 | CNY 13.5M | 0.13 | 49.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 13, 2023.
Who owns Hunan Nucien Pharmaceutical Co Ltd
- Insiders 50.82%
- Institutions 16.30%
- Public & others 32.89%
- Shares outstanding 273M
- Free float 152M
Hunan Nucien Pharmaceutical Co Ltd company profile
- Company name
- Hunan Nucien Pharmaceutical Co Ltd
- Ticker
- 688189.SHG
- ISIN
- CNE100007713
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 302
- Fiscal year end
- December
- Address
- Building 1-2, Guangzhou, China, 510100
- Phone
- 86 20 3895 2000
- Website
- nucien.com
About Hunan Nucien Pharmaceutical Co Ltd
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascular, antibiotics, antipyretics, pain relief, diabetes, analgesic, cerebrovascular, respiratory, and other pharmaceutical fields. Hunan Nucien Pharmaceutical Co., Ltd. was founded in 2006 and is based in Guangzhou, China.
Hunan Nucien Pharmaceutical Co Ltd management
6- Mr. Liang LiDeputy GM & CFO · born 1976
- Mr. Shi JianDeputy General Manager · born 1977
- Mr. Shukao LiuDeputy General Manager · born 1981
- Mr. Xuan LiSecretary of the Board · born 1984
- Mr. Shi Xi ZhangVice Chairman & GM · born 1974
- Xiaoning ChenAccounting Supervisor